Could a leukemia drug stop deadly brain tumor spread?
NCT ID NCT07039760
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early study tests whether asciminib, a drug already approved for leukemia, can get into brain tumors in children and young adults (ages 6-25) with recurrent brain tumors. Some participants will also get sildenafil to see if it helps the drug enter the tumor. The main goal is to measure drug levels in tumor tissue after surgery, not to treat the tumor itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib with or without sildenafil
What this could lead to
If it works, this could point toward a way to treat brain tumors that have spread, by helping the drug reach the tumor in higher amounts.
What could go wrong
This is a very early, small study (12 people) that only measures drug levels in the tumor, not whether the drug actually shrinks tumors or improves survival. It may not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine/St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact